Mitomycin C in advanced breast cancer: an update
Godfrey, T.E.
Seminars in Oncology 15(3 Suppl. 4): 71-73
1988
ISSN/ISBN: 0093-7754 PMID: 3134697 Document Number: 313023
Mitomycin C has a documented response rate of 20% to 30% when used as treatment in advanced breast cancer. Because of its delayed and cumulative hematologic toxicity, there has been a reluctance to use this agent. However, by lowering the drug dosage, the hematologic, pulmonary, and renal toxicities have been reduced. The reduced dosage does not appear to have compromised the treatment results.
Document emailed within 1 workday
Related Documents
Garewal, H.S. 1988: Mitomycin C in the chemotherapy of advanced breast cancer Seminars in Oncology 15(3 Suppl 4: 74-79Brambilla, C.; Zambetti, M.; Ferrari, L.; Bonadonna, G. 1989: Mitomycin C and vinblastine in advanced refractory breast cancer Tumori 75(2): 141-144
Chagpar, A.B. 2007: Insights into the management of locally advanced, inflammatory, and metastatic breast cancer: highlights from the 2007 Louisville Breast Cancer Update Journal of the Kentucky Medical Association 105(11): 559-560
Dieras, V.; Marty, M.; Tubiana, N.; Corette, L.; Morvan, F.; Serin, D.; Mignot, L.; Chazard, M.; Garet, F.; Onetto, N. 1995: Phase Ii randomized study of paclitaxel versus mitomycin in advanced breast cancer Seminars in Oncology 22(4 Suppl 8: 33-39
Lawson, D.; Moore, M.; Smalley, R. 1980: An evaluation of hexamethylmelamine, cis-diamminedichloroplatinum, and mitomycin-C in advanced breast cancer. a pilot study of the Southeastern Cancer Study Group Cancer Clinical Trials 3(4): 293-296
Jin, M.L.; Yang, B.Q.; Zhang, W.; Ren, P. 1992: High dose mitomycin C for treatment of advanced gastric cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(8 Suppl): 1193-1196
Maiello, E.; Giotta, F.; Gebbia, V.; Testa, A.; Galetta, D.; Riccardi, F.; Gebbia, N.; Colucci, G. 1996: Mitomycin C and lonidamine as second-line treatment of advanced colorectal cancer patients Anticancer Research 16(5b): 3177-3179
Soh, L.T.; Tan, E.H.; Ang, P.T. 1998: Mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer Singapore Medical Journal 39(8): 357-358
Reiner, A.S.; Sisti, J.; John, E.M.; Lynch, C.F.; Brooks, J.D.; Mellemkjær, L.; Boice, J.D.; Knight, J.A.; Concannon, P.; Capanu, M.; Tischkowitz, M.; Robson, M.; Liang, X.; Woods, M.; Conti, D.V.; Duggan, D.; Shore, R.; Stram, D.O.; Thomas, D.C.; Malone, K.E.; Bernstein, L.; Bernstein, J.L. 2018: Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 36(15): 1513-1520
Ozeki, H.; Ogawa, M.; Horikoshi, N.; Inoue, K.; Mukaiyama, T.; Nagamine, D.; Ito, Y.; Imajo, K.; Shinagawa, K. 1988: Combination chemotherapy of 5-fluorouracil (5-FU), adriamycin (ADM), cis-diamminedichloroplatinum (II) (CDDP) and mitomycin C (MMC) (FAP.MMC) in advanced gastric cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(1): 91-95
Stamatovic, L.; Susnjar, S.; Gavrilovic, D.; Minic, I.; Ursulovic, T.; Dzodic, R. 2018: The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients Journal of Buon: Official Journal of the Balkan Union of Oncology 23(5): 1273-1280
Grieco, A.; Lasorella, A.; Astone, A.; Vagliviello, L.; Bartoloni, C.; Barone, C. 1984: Chemotherapy of gastrointestinal cancer in the advanced stage with a combination of 5-fluorouracil, adriamycin, mitomycin C (FAM). a non-controlled study La Clinica Terapeutica 110(4): 353-358
Ota, K.; Kurita, S.; Nishimura, M.; Ogawa, M.; Kamei, Y.; Imai, K.; Ariyoshi, Y.; Kataoka, K.; Murakami, M.; Oyama, A.; Hoshino, A.; Amo, H.; Kato, T. 1972: Combination therapy with mitomycin C (NSC-26980), 5-fluorouracil (NSC-19893), and cytosine arabinoside (NSC-63878) for advanced cancer in man Cancer ChemoTherapy Reports 56(3): 373-385
Albeshan, S.M.; Hossain, S.Z.; Mackey, M.G.; Brennan, P.C. 2020: Can Breast Self-examination and Clinical Breast Examination Along with Increasing Breast Awareness Facilitate Earlier Detection of Breast Cancer in Populations with Advanced Stages at Diagnosis? Clinical Breast Cancer 20(3): 194-200
Maekawa, S.; Saku, M.; Kinugasa, T.; Yoshida, Y.; Ikejiri, K.; Yakabe, S. 1990: A case report of advanced gastric cancer remarkably responding to mitomycin C, aclacinomycin A, SF-SP and lentinan combination therapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 17(1): 137-140
2004: Adjuvant chemotherapy for early breast cancer: protocol and nonprotocol treatment options. Proceedings of a national research leader think tank and 3 regional breast cancer update working group meetings. July-October 2003 Oncology 18(4 Suppl. 1): 5-22
Shimizu, Y.; Nakayama, K.; Seimiya, Y.; Yamakawa, Y.; Koi, S.; Yokosuka, K.; Teshima, H.; Chen, J.T.; Fujimoto, I.; Yamauchi, K. 1991: Treatment of advanced or recurrent cervical cancer by a new BOMP regimen consisting of bleomycin, vincristine, mitomycin-C, and low-dose consecutive cisplatin Nihon Sanka Fujinka Gakkai Zasshi 43(5): 549-556
Gagliano, R.G.; Panettiere, F.J.; Haas, C.D.; Baker, L.; Hewlett, J.; Stuckey, W.J.; O'Bryan, R.M.; Bottomley, R.; Heilburn, L.K. 1981: Evaluation of beta-2'-deoxythioguanosine combined with methyl-CCNU or mitomycin in advanced colorectal cancer. a Southwest Oncology Group study Cancer Clinical Trials 4(4): 401-405
Kurihara, M.; Kosaki, G.; Taguchi, T.; Akazawa, S.; Sasaki, T.; Takahashi, H.; Onodera, T.; Endo, M.; Nakagawara, G.; Sano, K. 1995: Quality of life in patients with advanced gastric cancer receiving AO-90, a methionine-free intravenous amino acid solution, with 5-fluorouracil and mitomycin C Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(7): 911-923
Taguchi, T.; Koyama, H.; Yayoi, K.; Wada, T.; Takatsuka, Y.; Sonoo, H.; Morimoto, K.; Tominaga, T.; Abe, R.; Enomoto, K. 1995: Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(4): 495-508